IGC Pharma (IGC) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed IGC Pharma (IGC) over the past year, gaining 2.8% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -91.1% for MRKR. IGC Pharma is the larger company by market cap ($19.6 million vs $18.2 million), about 1.1 times the size.
Marker Therapeutics converts more of its revenue into profit, with a net margin of -343.0% versus -560.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IGC | MRKR |
|---|---|---|
| Share price | $0.168 | $1.09 |
| Market cap | $19.60M | $18.17M |
| 1-day change | -8.70% | -17.42% |
| YTD return | -40.00% | -26.85% |
| 1-year return | -47.50% | +2.83% |
| 5-year return | -87.65% | -91.14% |
| EPS (TTM) | $-0.07 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.27M | $3.55M |
| Revenue growth (YoY) | -5.50% | -46.19% |
| Net income (latest FY) | $-7.12M | $-12.16M |
| Gross margin | 48.70% | — |
| Operating margin | -585.84% | -363.45% |
| Net margin | -560.35% | -342.96% |
| 52-week high | $0.36 | $2.46 |
| 52-week low | $0.08 | $0.81 |
| Distance from 52-week high | -53.33% | -55.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +3471.43% | +622.02% |
| Average volume | 615.25K | 711.96K |
| Shares outstanding | 116.69M | 16.67M |
| Employees | 70 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed IGC by 50.3 percentage points over the past year.
- Marker Therapeutics is more profitable, keeping -343.0 cents of every revenue dollar as net income versus -560.3 cents for IGC Pharma.
- IGC Pharma grew revenue faster in its latest fiscal year (-5.50% vs -46.19%).
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
IGC vs MRKR FAQ
Which is bigger, IGC Pharma or Marker Therapeutics?
IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.17M for Marker Therapeutics (MRKR).
Which stock has performed better over the past year, IGC or MRKR?
MRKR returned +2.83% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.
Are IGC Pharma and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.